This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Kexing Biopharm GB10 Phase I Trial
Business clinical trial

Kexing Biopharm GB10 Phase I Trial

Analysis based on 7 articles · First reported Jun 04, 2026 · Last updated Jun 04, 2026

Sentiment
60
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The initiation of Phase I clinical trials for GB10 Injection by Shenzhen Kexing Pharmaceutical Co., Ltd., a subsidiary of Kexing Biopharm, is a positive development for the pharmaceutical and biotechnology sectors. This could lead to increased investor confidence in Kexing Biopharm's R&D capabilities and future market potential, especially given the high demand for ophthalmic treatments.

Pharmaceuticals Biotechnology
Event Summary

Shenzhen Kexing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Kexing Biopharm, has enrolled and dosed the first subject in a Phase I clinical trial in China for its innovative ophthalmic drug, GB10 Injection. This drug is designed to treat neovascular age-related macular degeneration (nAMD), a leading cause of blindness. GB10 Injection is a high-concentration, bispecific antibody targeting both VEGF and Ang-2, with preclinical data showing international competitiveness. Its expected 'once per four months' dosing schedule aims to significantly improve patient compliance, addressing a critical clinical pain point. This milestone accelerates Kexing Biopharm's innovative drug R&D pipeline and supports its strategy to expand its global footprint through continuous innovation, including introducing other ophthalmic products like Aflibercept biosimilar and Olopatadine Hydrochloride eye drops.

Entities Involved
stock
Kexing Biopharm
Kexing Biopharm is the parent company whose subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., developed GB10 Injection. This event marks a significant milestone in its innovative drug R&D pipeline, potentially expanding its global footprint and driving internationalization.
Importance 100.0 Sentiment 70.0
stock
Shenzhen Kexing Pharmaceutical Co., Ltd.
Shenzhen Kexing Pharmaceutical Co., Ltd. independently developed GB10 Injection, an innovative ophthalmic drug. The enrollment of the first subject in its Phase I clinical trial is a key achievement for the company.
Importance 90.0 Sentiment 70.0
oth
GB10 Injection
GB10 Injection is an innovative ophthalmic drug developed by Shenzhen Kexing Pharmaceutical Co., Ltd. that has entered Phase I clinical trials in China for treating neovascular age-related macular degeneration (nAMD). Its potential for extended dosing intervals could significantly improve patient compliance.
Importance 85.0 Sentiment 60.0
cnt
China
China is the location where the Phase I clinical trial for GB10 Injection is being conducted.
Importance 30.0 Sentiment 0.0
oth
Aflibercept biosimilar
Aflibercept biosimilar are among the externally developed ophthalmic products that Kexing Biopharm is actively introducing for international markets.
Importance 10.0 Sentiment 0.0
oth
Olopatadine Hydrochloride eye drops
Olopatadine Hydrochloride eye drops are among the externally developed ophthalmic products that Kexing Biopharm is actively introducing for international markets.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.